{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "65565858",
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "import dspy\n",
    "import pandas as pd\n",
    "\n",
    "from agentic_system.agents import CFEfficacyAgent\n",
    "\n",
    "load_dotenv(\"../.env\")\n",
    "dspy.configure(lm=dspy.LM(\"gemini/gemini-2.5-flash-lite\", temperature=0.5, cache=True))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "fe5bc34b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>compound_name</th>\n",
       "      <th>percent_remaining_cells</th>\n",
       "      <th>cf_efficacy</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Luminespib</td>\n",
       "      <td>22.799240</td>\n",
       "      <td>0.938466</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Tanespimycin</td>\n",
       "      <td>22.545915</td>\n",
       "      <td>0.930389</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>MK-2866</td>\n",
       "      <td>85.687144</td>\n",
       "      <td>0.862550</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Navitoclax</td>\n",
       "      <td>52.754908</td>\n",
       "      <td>0.802508</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Finasteride</td>\n",
       "      <td>69.221026</td>\n",
       "      <td>0.763109</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  compound_name  percent_remaining_cells  cf_efficacy\n",
       "0    Luminespib                22.799240     0.938466\n",
       "1  Tanespimycin                22.545915     0.930389\n",
       "2       MK-2866                85.687144     0.862550\n",
       "3    Navitoclax                52.754908     0.802508\n",
       "4   Finasteride                69.221026     0.763109"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "LITL_DATA_PATH = \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/agentic_system/litl_data/litl_data.csv\"\n",
    "\n",
    "litl_df = pd.read_csv(LITL_DATA_PATH)\n",
    "litl_df.head(5)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "4a63cc03",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Example({'compound_name': 'Luminespib', 'cf_efficacy': 0.9384660045676458}) (input_keys={'compound_name'}),\n",
       " Example({'compound_name': 'Tanespimycin', 'cf_efficacy': 0.9303885695518936}) (input_keys={'compound_name'}),\n",
       " Example({'compound_name': 'MK-2866', 'cf_efficacy': 0.8625497422790986}) (input_keys={'compound_name'}),\n",
       " Example({'compound_name': 'Navitoclax', 'cf_efficacy': 0.8025081640919406}) (input_keys={'compound_name'}),\n",
       " Example({'compound_name': 'Finasteride', 'cf_efficacy': 0.7631090441879179}) (input_keys={'compound_name'})]"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "efficacy_devset = []\n",
    "for _, row in litl_df.iterrows():\n",
    "    efficacy_devset.append(\n",
    "        dspy.Example(\n",
    "            compound_name=row[\"compound_name\"],\n",
    "            cf_efficacy=row[\"cf_efficacy\"],\n",
    "        ).with_inputs(\"compound_name\")\n",
    "    )\n",
    "\n",
    "efficacy_devset[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "690fcf01",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "  0%|          | 0/10 [00:00<?, ?it/s]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:51 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Tanespimycin', 'cf_efficacy': 0.9303885695518936}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  10%|█         | 1/10 [00:07<01:09,  7.69s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:52 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Veliparib', 'cf_efficacy': 0.718292313566172}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  20%|██        | 2/10 [00:08<00:28,  3.53s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:55 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'KU-55933', 'cf_efficacy': 0.6758212843500732}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  30%|███       | 3/10 [00:11<00:22,  3.22s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:56 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'PHA-665752', 'cf_efficacy': 0.6482624882747973}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  40%|████      | 4/10 [00:12<00:14,  2.39s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:56 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'MK-2866', 'cf_efficacy': 0.8625497422790986}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  40%|████      | 4/10 [00:12<00:14,  2.39s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:56 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Luminespib', 'cf_efficacy': 0.9384660045676458}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  60%|██████    | 6/10 [00:12<00:04,  1.20s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:58 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Nilotinib', 'cf_efficacy': 0.6380639938634679}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  70%|███████   | 7/10 [00:14<00:03,  1.28s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:49:58 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Navitoclax', 'cf_efficacy': 0.8025081640919406}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  80%|████████  | 8/10 [00:14<00:02,  1.07s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:50:01 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'Finasteride', 'cf_efficacy': 0.7631090441879179}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%):  90%|█████████ | 9/10 [00:17<00:01,  1.57s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:50:02 ERROR dspy.utils.parallelizer: Error for Example({'compound_name': 'GSK1904529A', 'cf_efficacy': 0.6779650234402858}) (input_keys={'compound_name'}): 'NoneType' object is not callable\n",
      "Traceback (most recent call last):\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py\", line 55, in safe_func\n",
      "    return user_function(item)\n",
      "           ^^^^^^^^^^^^^^^^^^^\n",
      "  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py\", line 159, in process_item\n",
      "    score = metric(example, prediction)\n",
      "            ^^^^^^^^^^^^^^^^^^^^^^^^^^^\n",
      "TypeError: 'NoneType' object is not callable\n",
      "\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Average Metric: 0.00 / 0 (0%): 100%|██████████| 10/10 [00:18<00:00,  1.84s/it]"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "2025/09/15 14:50:02 WARNING dspy.utils.parallelizer: Execution cancelled due to errors or interruption.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "ename": "Exception",
     "evalue": "Execution cancelled due to errors or interruption.",
     "output_type": "error",
     "traceback": [
      "\u001b[31m---------------------------------------------------------------------------\u001b[39m",
      "\u001b[31mException\u001b[39m                                 Traceback (most recent call last)",
      "\u001b[36mCell\u001b[39m\u001b[36m \u001b[39m\u001b[32mIn[10]\u001b[39m\u001b[32m, line 20\u001b[39m\n\u001b[32m     11\u001b[39m evaluator = Evaluate(\n\u001b[32m     12\u001b[39m     devset=efficacy_devset[:\u001b[32m10\u001b[39m],\n\u001b[32m     13\u001b[39m     num_threads=\u001b[32m10\u001b[39m,\n\u001b[32m   (...)\u001b[39m\u001b[32m     16\u001b[39m     provide_traceback=\u001b[38;5;28;01mTrue\u001b[39;00m,\n\u001b[32m     17\u001b[39m )\n\u001b[32m     19\u001b[39m efficacy_agent = CFEfficacyAgent(max_iters=\u001b[32m5\u001b[39m)\n\u001b[32m---> \u001b[39m\u001b[32m20\u001b[39m evaluation = \u001b[43mevaluator\u001b[49m\u001b[43m(\u001b[49m\u001b[43mefficacy_agent\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m     21\u001b[39m evaluation\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/callback.py:326\u001b[39m, in \u001b[36mwith_callbacks.<locals>.sync_wrapper\u001b[39m\u001b[34m(instance, *args, **kwargs)\u001b[39m\n\u001b[32m    324\u001b[39m callbacks = _get_active_callbacks(instance)\n\u001b[32m    325\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m callbacks:\n\u001b[32m--> \u001b[39m\u001b[32m326\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfn\u001b[49m\u001b[43m(\u001b[49m\u001b[43minstance\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43m*\u001b[49m\u001b[43m*\u001b[49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    328\u001b[39m call_id = uuid.uuid4().hex\n\u001b[32m    330\u001b[39m _execute_start_callbacks(instance, fn, call_id, callbacks, args, kwargs)\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/evaluate/evaluate.py:162\u001b[39m, in \u001b[36mEvaluate.__call__\u001b[39m\u001b[34m(self, program, metric, devset, num_threads, display_progress, display_table, callback_metadata)\u001b[39m\n\u001b[32m    159\u001b[39m     score = metric(example, prediction)\n\u001b[32m    160\u001b[39m     \u001b[38;5;28;01mreturn\u001b[39;00m prediction, score\n\u001b[32m--> \u001b[39m\u001b[32m162\u001b[39m results = \u001b[43mexecutor\u001b[49m\u001b[43m.\u001b[49m\u001b[43mexecute\u001b[49m\u001b[43m(\u001b[49m\u001b[43mprocess_item\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mdevset\u001b[49m\u001b[43m)\u001b[49m\n\u001b[32m    163\u001b[39m \u001b[38;5;28;01massert\u001b[39;00m \u001b[38;5;28mlen\u001b[39m(devset) == \u001b[38;5;28mlen\u001b[39m(results)\n\u001b[32m    165\u001b[39m results = [((dspy.Prediction(), \u001b[38;5;28mself\u001b[39m.failure_score) \u001b[38;5;28;01mif\u001b[39;00m r \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m \u001b[38;5;28;01melse\u001b[39;00m r) \u001b[38;5;28;01mfor\u001b[39;00m r \u001b[38;5;129;01min\u001b[39;00m results]\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py:48\u001b[39m, in \u001b[36mParallelExecutor.execute\u001b[39m\u001b[34m(self, function, data)\u001b[39m\n\u001b[32m     46\u001b[39m tqdm.tqdm._instances.clear()\n\u001b[32m     47\u001b[39m wrapped = \u001b[38;5;28mself\u001b[39m._wrap_function(function)\n\u001b[32m---> \u001b[39m\u001b[32m48\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[38;5;28;43mself\u001b[39;49m\u001b[43m.\u001b[49m\u001b[43m_execute_parallel\u001b[49m\u001b[43m(\u001b[49m\u001b[43mwrapped\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mdata\u001b[49m\u001b[43m)\u001b[49m\n",
      "\u001b[36mFile \u001b[39m\u001b[32m~/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/parallelizer.py:203\u001b[39m, in \u001b[36mParallelExecutor._execute_parallel\u001b[39m\u001b[34m(self, function, data)\u001b[39m\n\u001b[32m    201\u001b[39m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m.cancel_jobs.is_set():\n\u001b[32m    202\u001b[39m     logger.warning(\u001b[33m\"\u001b[39m\u001b[33mExecution cancelled due to errors or interruption.\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m--> \u001b[39m\u001b[32m203\u001b[39m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m(\u001b[33m\"\u001b[39m\u001b[33mExecution cancelled due to errors or interruption.\u001b[39m\u001b[33m\"\u001b[39m)\n\u001b[32m    205\u001b[39m \u001b[38;5;28;01mreturn\u001b[39;00m results\n",
      "\u001b[31mException\u001b[39m: Execution cancelled due to errors or interruption."
     ]
    }
   ],
   "source": [
    "from dspy.evaluate import Evaluate\n",
    "\n",
    "\n",
    "def efficacy_accuracy(example, pred, trace=None):\n",
    "    \"Calculate error from prediction\"\n",
    "    abs_error = abs(example.cf_efficacy - float(pred.predicted_efficacy))\n",
    "    accuracy = 1 - abs_error\n",
    "    return accuracy\n",
    "\n",
    "\n",
    "# Set up the evaluator, which can be re-used in your code.\n",
    "evaluator = Evaluate(\n",
    "    devset=efficacy_devset[:10],\n",
    "    num_threads=10,\n",
    "    display_progress=True,\n",
    "    display_table=5,\n",
    "    provide_traceback=True,\n",
    ")\n",
    "\n",
    "efficacy_agent = CFEfficacyAgent(max_iters=5)\n",
    "evaluation = evaluator(efficacy_agent, metric=efficacy_accuracy)\n",
    "evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "8495d2cc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[(Example({'compound_name': 'Luminespib', 'cf_efficacy': 0.9384660045676458}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': \"The user wants to estimate the efficacy of Luminespib in reversing the activated cardiac fibroblast phenotype. The provided assay details describe a specific in vitro experiment. To assess efficacy, I need to find any existing preclinical data on Luminespib's effects on cardiac fibroblasts or fibrosis. I will start by searching for Luminespib in ChEMBL to get its ChEMBL ID, which can then be used to retrieve more detailed information.\", 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Luminespib'}, 'observation_0': \"Found 2 compound(s) matching 'Luminespib': \\n - CHEMBL3137334 (LUMINESPIB MESYLATE)\\n - CHEMBL252164 (LUMINESPIB)\", 'thought_1': 'I have found two ChEMBL IDs for Luminespib: CHEMBL3137334 and CHEMBL252164. I should investigate both to gather comprehensive information. I will start by getting the compound properties for CHEMBL252164, as it is the more general identifier.', 'tool_name_1': 'CHEMBL__get_compound_properties', 'tool_args_1': {'chembl_id': 'CHEMBL252164'}, 'observation_1': \"Properties of CHEMBL252164:. molecular weight 465.6 Da. ALogP 4.13 (lipophilic). TPSA 108.1 Ų (moderate permeability expected). 3 H-bond donors and 7 H-bond acceptors. 7 rotatable bonds (flexible). compliant with Lipinski's Rule of Five. classified as Small molecule.\", 'thought_2': \"I have retrieved the properties for CHEMBL252164. Now I will retrieve the properties for CHEMBL3137334 to see if there's any significant difference.\", 'tool_name_2': 'CHEMBL__get_compound_properties', 'tool_args_2': {'chembl_id': 'CHEMBL3137334'}, 'observation_2': \"Properties of CHEMBL3137334:. molecular weight 465.6 Da. ALogP 4.13 (lipophilic). TPSA 108.1 Ų (moderate permeability expected). 3 H-bond donors and 7 H-bond acceptors. 7 rotatable bonds (flexible). compliant with Lipinski's Rule of Five. classified as Small molecule.\", 'thought_3': 'The properties for both ChEMBL IDs are identical. This suggests they refer to the same compound, with CHEMBL3137334 being a salt form. To assess efficacy, I need to find bioactivity data related to cardiac fibroblasts or fibrosis. I will now search for bioactivities of CHEMBL252164.', 'tool_name_3': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_3': {'chembl_id': 'CHEMBL252164'}, 'observation_3': 'Bioactivity summary for CHEMBL252164:\\n\\n• ADMET (CHEMBL612558): Cmax_tumor = 6.0 uM, Drug uptake = 6.8 uM, Vz = 0.4 l, T1/2 = 15.0 hr, AUC = 16760 ng.hr.mL-1, CL = 2.00e-02 L/hr, Stability = 31.0 %\\n\\n• Mus musculus (CHEMBL375): Tmax = 1.0 hr, Activity = 10.0 %, Cmax = 385.4 nM, MTD = 50.0 mg kg-1, CL/F = 3.50e-02 L/hr, T1/2 = 9.5 hr, AUC = 800.8 ng.hr.mL-1, Vdss = 0.5 l, LBF = 108.0 ml/hr\\n\\n• Plasma (CHEMBL613589): Cmax = 49000 nM, Vz = 0.9 l, T1/2 = 1.0 hr, AUC = 6983 ng.hr.mL-1, CL = 8.20e-02 L/hr\\n\\n• Heat shock protein HSP 90-beta (CHEMBL4303): IC50 = 7.0 nM, Ki = 6.40e-02 nM\\n\\n• HCT-116 (CHEMBL394): GI50 = 16.0 nM, GI = 50.0 %, Inhibition = 49.8 %\\n(Showing top 5 of 14 targets with activity data)', 'thought_4': \"The bioactivity summary shows Luminespib's activity against HSP 90-beta (IC50 = 7.0 nM) and in HCT-116 cells (GI50 = 16.0 nM). However, there is no direct information about its efficacy in reversing cardiac fibroblast phenotype or in a cardiac fibrosis context. I need to search for drug information and safety summaries to see if there's any relevant information, and also check for similar compounds that might have been studied in this context.\", 'tool_name_4': 'PUBCHEM__get_drug_summary', 'tool_args_4': {'cid': 'CHEMBL252164'}, 'observation_4': 'No drug information available for CID CHEMBL252164'},\n",
       "      reasoning='Luminespib is a known inhibitor of Heat Shock Protein 90 (HSP90). While HSP90 plays a role in cellular stress responses, and its inhibition can have broad cellular effects, there is no direct evidence in the provided ChEMBL data linking Luminespib to the modulation of cardiac fibroblast activation or fibrosis. The bioactivity data focuses on HSP90 inhibition and general cellular cytotoxicity (GI50 in HCT-116 cells). Without specific studies on cardiac fibroblasts or fibrosis, it is not possible to predict efficacy for this particular assay. Therefore, the predicted efficacy is 0, and the confidence is low due to the lack of relevant data.',\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.1\n",
       "  ),\n",
       "  0.9384660045676458),\n",
       " (Example({'compound_name': 'Tanespimycin', 'cf_efficacy': 0.9303885695518936}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to assess the efficacy of Tanespimycin in reversing the activated cardiac fibroblast phenotype. The provided assay details describe a specific in vitro experiment. To predict efficacy, I need to find any existing preclinical data on Tanespimycin in a cardiac fibrosis context. I will start by searching for Tanespimycin in ChEMBL to get its ChEMBL ID, which will allow me to retrieve more detailed information.', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Tanespimycin'}, 'observation_0': \"Found 2 compound(s) matching 'Tanespimycin': \\n - CHEMBL4786163 (None)\\n - CHEMBL109480 (TANESPIMYCIN)\", 'thought_1': \"I have found two ChEMBL IDs for Tanespimycin: CHEMBL4786163 and CHEMBL109480. CHEMBL109480 is explicitly labeled as TANESPIMYCIN, so I will proceed with this ID. The next step is to get more information about this compound, specifically its bioactivities, to see if there's any data related to cardiac fibroblasts or fibrosis.\", 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL109480'}, 'observation_1': 'Bioactivity summary for CHEMBL109480:\\n\\n• Heat shock protein HSP90 (CHEMBL2095165): EC50 = 19.0 nM, IC50 = 7.0 nM\\n\\n• SK-BR-3 (CHEMBL613834): GI50 = 17.0 nM, IC50 = 31.0 nM, Inhibition = 55.0 %\\n\\n• Mus musculus (CHEMBL375): Inhibition = 27.0 %\\n\\n• HCT-116 (CHEMBL394): GI50 = 21.0 nM, IC50 = 170.0 nM\\n\\n• Heat shock protein HSP 90-alpha (CHEMBL3880): EC50 = 64.9 nM, IC50 = 1270 nM\\n(Showing top 5 of 18 targets with activity data)', 'thought_2': 'The bioactivity summary for Tanespimycin (CHEMBL109480) shows that it is a potent inhibitor of Heat Shock Protein 90 (HSP90). While this is a significant finding, the provided bioactivities do not directly relate to cardiac fibroblasts or fibrosis. The task requires assessing efficacy in reversing the activated cardiac fibroblast phenotype. Since direct evidence is lacking, I will search on PubChem for Tanespimycin to see if there are any relevant bioassays or drug information that might shed light on its effects in cardiac-related conditions.', 'tool_name_2': 'PUBCHEM__search_pubchem_cid', 'tool_args_2': {}, 'observation_2': 'Execution error in PUBCHEM__search_pubchem_cid: \\nTraceback (most recent call last):\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/predict/react.py\", line 111, in forward\\n    trajectory[f\"observation_{idx}\"] = self.tools[pred.next_tool_name](**pred.next_tool_args)\\n                                       ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/callback.py\", line 326, in sync_wrapper\\n    return fn(instance, *args, **kwargs)\\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/adapters/types/tool.py\", line 176, in __call__\\n    result = self.func(**parsed_kwargs)\\n             ^^^^^^^^^^^^^^^^^^^^^^^^^^\\nTypeError: search_pubchem_cid() missing 1 required positional argument: \\'query\\'', 'thought_3': 'The previous tool call to `PUBCHEM__search_pubchem_cid` failed because the `query` argument was missing. I need to provide the compound name, \"Tanespimycin\", as the query to search PubChem.', 'tool_name_3': 'PUBCHEM__search_pubchem_cid', 'tool_args_3': {'query': 'Tanespimycin'}, 'observation_3': \"Found PubChem CID 6505803 ([(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13-hydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18-pentaen-9-yl] carbamate) for 'Tanespimycin'\", 'thought_4': 'I have found the PubChem CID for Tanespimycin (6505803). The next step is to retrieve its bioassay summary to check for any relevant data related to cardiac fibroblasts or fibrosis.', 'tool_name_4': 'PUBCHEM__get_bioassay_summary', 'tool_args_4': {'cid': '6505803'}, 'observation_4': 'Bioassay summary for CID 6505803:\\nTested in 1407 assays - 890 active, 168 inactive\\n\\nActive in:\\n• AID 1: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell ... \\n\\n• AID 5: NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cel... \\n\\n• AID 7: NCI human tumor cell line growth inhibition assay. Data for the NCI-H460 Non-Small Cell Lung cell... \\n\\n• AID 9: NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line \\n\\n• AID 15: NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell... \\n\\n(Showing 5 of 890 active assays)'},\n",
       "      reasoning='Tanespimycin is a known inhibitor of Heat Shock Protein 90 (HSP90). While its mechanism of action is well-established and it has been tested in numerous growth inhibition assays, there is no direct preclinical evidence in the provided search results linking Tanespimycin to cardiac fibroblasts or the reversal of cardiac fibrosis. The available data primarily focuses on cancer cell line growth inhibition. Therefore, predicting its efficacy in the context of cardiac fibroblast activation is speculative due to the lack of specific data.',\n",
       "      predicted_efficacy=0.1,\n",
       "      confidence=0.2\n",
       "  ),\n",
       "  0.8303885695518937),\n",
       " (Example({'compound_name': 'MK-2866', 'cf_efficacy': 0.8625497422790986}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': \"The user wants to estimate the efficacy of MK-2866 in reversing the activated cardiac fibroblast phenotype. The provided assay details are specific and quantitative. To begin, I need to find information about MK-2866, specifically its known activities and properties, to see if there's any existing preclinical data relevant to cardiac fibrosis or fibroblast activation. I will start by searching for MK-2866 on both ChEMBL and PubChem to get its ChEMBL ID and PubChem CID.\", 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'MK-2866'}, 'observation_0': \"Found 5 compound(s) matching 'MK-2866': \\n - CHEMBL578711 (None)\\n - CHEMBL1738889 (ENOBOSARM)\\n - CHEMBL2109437 (KHK-2866)\\n - CHEMBL3188657 (None)\\n - CHEMBL4591460 (None)\", 'thought_1': 'MK-2866 appears to be known by other names, such as Ostarine (ENOBOSARM) and KHK-2866. To proceed, I need to clarify which of these is the most relevant compound. I will search for the PubChem CID for MK-2866 to gather more information.', 'tool_name_1': 'PUBCHEM__search_pubchem_cid', 'tool_args_1': {'query': 'MK-2866'}, 'observation_1': \"Found PubChem CID 11326715 ((2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide) for 'MK-2866'\", 'thought_2': 'I have found a PubChem CID for MK-2866. Now I need to retrieve its properties and bioactivity summaries from both ChEMBL and PubChem to assess its relevance to cardiac fibrosis and fibroblast activation. I will start by getting the compound properties from PubChem using the CID 11326715.', 'tool_name_2': 'PUBCHEM__get_cid_properties', 'tool_args_2': {'cid': '11326715'}, 'observation_2': 'Properties of PubChem CID 11326715:. molecular formula C19H14F3N3O3 with MW 389.30 g/mol. XLogP 2.70 (moderate lipophilicity). TPSA 106.0 Å² (moderate permeability expected). 2 H-bond donors and 8 H-bond acceptors. 5 rotatable bonds (moderate flexibility). molecular complexity 658 (complex).', 'thought_3': \"I have retrieved the basic properties of MK-2866 from PubChem. Now, I need to find its ChEMBL ID to access more detailed bioactivity data from ChEMBL. I will use the information from the previous ChEMBL search to identify the correct ChEMBL ID. CHEMBL578711 is listed as 'None' which is not helpful, CHEMBL1738889 is 'ENOBOSARM' (Ostarine), and CHEMBL2109437 is 'KHK-2866'. Given that the PubChem search returned MK-2866, I will assume that CHEMBL1738889 (Ostarine) is the most relevant entry. I will now fetch the compound properties and bioactivities for this ChEMBL ID.\", 'tool_name_3': 'CHEMBL__get_compound_properties', 'tool_args_3': {'chembl_id': 'CHEMBL1738889'}, 'observation_3': \"Properties of CHEMBL1738889:. molecular weight 389.3 Da. ALogP 3.22 (lipophilic). TPSA 106.1 Ų (moderate permeability expected). 2 H-bond donors and 5 H-bond acceptors. 5 rotatable bonds (moderate flexibility). compliant with Lipinski's Rule of Five. classified as Small molecule.\", 'thought_4': 'I have retrieved the properties for MK-2866 (Ostarine) from both PubChem and ChEMBL. The properties are consistent. Now I need to find its bioactivity data to assess its efficacy in reversing the activated cardiac fibroblast phenotype. I will start by getting a summary of bioactivities from ChEMBL for CHEMBL1738889.', 'tool_name_4': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_4': {'chembl_id': 'CHEMBL1738889'}, 'observation_4': 'Bioactivity summary for CHEMBL1738889:\\n\\n• Androgen Receptor (CHEMBL1871): IC50 = 3.0 nM, Activity = 1.5 nM, Ratio = 60.0 None, Inhibition = -2.50e+01 %, Ki = 0.6 nM, RBA = 5.5 %\\n\\n• ADMET (CHEMBL612558): T1/2 = 6.0 hr, Papp = 26.7 ucm/s, Ratio = 0.8 None, CL = 1400 mL.min-1.g-1\\n\\n• SARS-CoV-2 (CHEMBL4303835): Inhibition = -6.00e-02 %\\n\\n• HepG2 (CHEMBL395): MEC = 21.8 uM, %max = 79.0 %, AC50 = 32800 nM\\n\\n• NON-PROTEIN TARGET (CHEMBL3879801): Activity = 142.0 %, Potency None 4.2 nM\\n(Showing top 5 of 12 targets with activity data)'},\n",
       "      reasoning=\"The user is asking to predict the efficacy of MK-2866 in reversing the activated cardiac fibroblast phenotype based on a Cell Painting assay. MK-2866 is identified as Ostarine (ENOBOSARM), a selective androgen receptor modulator (SARM). The ChEMBL bioactivity data shows that MK-2866 has very high affinity and activity for the androgen receptor (IC50 = 3.0 nM, Ki = 0.6 nM). SARMs are known to interact with androgen receptors, which play a role in muscle growth and repair. While there is no direct evidence in the provided data linking MK-2866 to cardiac fibroblast activation or reversal, androgens and their receptors have been implicated in cardiac remodeling and fibrosis. Some studies suggest that androgen receptor signaling can influence cardiac fibroblast function and extracellular matrix production. Given the potent activity of MK-2866 on the androgen receptor, it is plausible that it could exert some influence on cardiac fibroblasts. However, without direct experimental evidence from studies specifically addressing MK-2866's effect on cardiac fibroblasts or fibrosis, the prediction is based on a mechanistic inference. The efficacy is predicted to be moderate, assuming some beneficial effect on fibroblast phenotype due to androgen receptor modulation, but not complete reversal due to the lack of direct evidence. The confidence is moderate because while the compound is potent for its known target, its specific role in cardiac fibrosis is not well-established in the literature.\",\n",
       "      predicted_efficacy=0.45,\n",
       "      confidence=0.55\n",
       "  ),\n",
       "  0.41254974227909863),\n",
       " (Example({'compound_name': 'Navitoclax', 'cf_efficacy': 0.8025081640919406}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to assess the efficacy of Navitoclax in reversing the activated cardiac fibroblast phenotype. The provided description specifies a custom in vitro assay and readout. Since this is a custom assay, I first need to search for existing preclinical data on Navitoclax in a cardiac fibrosis context. I will start by searching ChEMBL for Navitoclax to get its ChEMBL ID.', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Navitoclax'}, 'observation_0': \"Found 2 compound(s) matching 'Navitoclax': \\n - CHEMBL2105690 (NAVITOCLAX DIHYDROCHLORIDE)\\n - CHEMBL443684 (NAVITOCLAX)\", 'thought_1': 'I have found two ChEMBL IDs for Navitoclax: CHEMBL2105690 and CHEMBL443684. I should investigate both to ensure I have comprehensive information. I will start by getting the compound properties for CHEMBL443684, as it is listed first and seems to be the primary entry.', 'tool_name_1': 'CHEMBL__get_compound_properties', 'tool_args_1': {'chembl_id': 'CHEMBL443684'}, 'observation_1': 'Properties of CHEMBL443684:. molecular weight 974.6 Da. ALogP 8.83 (lipophilic). TPSA 128.4 Ų (moderate permeability expected). 2 H-bond donors and 11 H-bond acceptors. 16 rotatable bonds (flexible). has 3 Ro5 violation(s). classified as Small molecule.', 'thought_2': 'I have retrieved the properties for CHEMBL443684. Now I will retrieve the properties for CHEMBL2105690 to see if there are any significant differences. After that, I will search for bioactivity data for both to understand their known effects, prioritizing any related to cardiac fibrosis.', 'tool_name_2': 'CHEMBL__get_compound_properties', 'tool_args_2': {'chembl_id': 'CHEMBL2105690'}, 'observation_2': 'Properties of CHEMBL2105690:. molecular weight 974.6 Da. ALogP 8.83 (lipophilic). TPSA 128.4 Ų (moderate permeability expected). 2 H-bond donors and 11 H-bond acceptors. 16 rotatable bonds (flexible). has 3 Ro5 violation(s). classified as Small molecule.', 'thought_3': \"The properties for both ChEMBL IDs (CHEMBL443684 and CHEMBL2105690) are identical. This suggests they refer to the same compound, possibly with different salt forms or simply different entries in the database. I will now proceed to get the bioactivity summary for CHEMBL443684 to find any relevant preclinical data, particularly concerning cardiac fibrosis. If I don't find relevant information, I will then check CHEMBL2105690.\", 'tool_name_3': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_3': {'chembl_id': 'CHEMBL443684'}, 'observation_3': 'Bioactivity summary for CHEMBL443684:\\n\\n• NON-PROTEIN TARGET (CHEMBL3879801): EC50 = 4.2 nM, TGI = 100.0 %, Potency None 4176 nM\\n\\n• Unchecked (CHEMBL612545): Ratio = 72.2 None, Potency None 5.9 nM\\n\\n• Rattus norvegicus (CHEMBL376): AUC = 6101 ng.hr.mL-1, T1/2 = 4.0 hr, F = 20.0 %\\n\\n• Mus musculus (CHEMBL375): AUC = 55262 ng.hr.mL-1, T1/2 = 4.0 hr, Activity < 5.0 %, F = 20.0 %\\n\\n• Canis familiaris (CHEMBL373): AUC = 27095 ng.hr.mL-1, T1/2 = 4.0 hr, F = 20.0 %\\n(Showing top 5 of 23 targets with activity data)', 'thought_4': 'The bioactivity summary for Navitoclax (CHEMBL443684) does not contain any specific information about its efficacy in reversing the activated cardiac fibroblast phenotype or any direct relevance to cardiac fibrosis. The listed activities are for non-protein targets and pharmacokinetic data in different species. To find relevant preclinical data, I should search for Navitoclax on PubChem and then look for bioassay summaries related to cardiac fibrosis or fibroblast activation. I will start by searching PubChem for Navitoclax.', 'tool_name_4': 'PUBCHEM__search_pubchem_cid', 'tool_args_4': {'query': 'Navitoclax'}, 'observation_4': \"Found PubChem CID 24978538 (4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide) for 'Navitoclax'\"},\n",
       "      reasoning=\"Navitoclax is a known inhibitor of BCL-2 family proteins, primarily investigated for its role in cancer therapy. A search of ChEMBL and PubChem did not reveal any direct preclinical data or studies specifically investigating Navitoclax's efficacy in reversing the activated cardiac fibroblast phenotype or its impact on cardiac fibrosis. The available bioactivity data from ChEMBL is not relevant to this specific context. Therefore, without direct evidence, predicting efficacy is not possible. The confidence in any prediction would be very low.\",\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.0\n",
       "  ),\n",
       "  0.8025081640919406),\n",
       " (Example({'compound_name': 'Finasteride', 'cf_efficacy': 0.7631090441879179}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': \"The user wants to assess the efficacy of Finasteride in reversing the activated cardiac fibroblast phenotype using a specific in vitro assay. The assay involves applying the compound to fibroblasts and measuring the reversion of the activated phenotype. To achieve this, I need to find information about Finasteride's effects on cardiac fibroblasts or related pathways. I will start by searching for Finasteride in ChEMBL to get its ChEMBL ID, which will allow me to access more detailed information.\", 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Finasteride'}, 'observation_0': \"Found 5 compound(s) matching 'Finasteride': \\n - CHEMBL74318 (None)\\n - CHEMBL4777013 (None)\\n - CHEMBL3542374 (None)\\n - CHEMBL710 (FINASTERIDE)\\n - CHEMBL114067 (None)\", 'thought_1': 'I have found multiple ChEMBL IDs for Finasteride. CHEMBL710 is explicitly labeled as \"FINASTERIDE\", making it the most likely candidate. I will now retrieve the compound properties for CHEMBL710 to confirm it\\'s the correct compound and gather basic information.', 'tool_name_1': 'CHEMBL__get_compound_properties', 'tool_args_1': {'chembl_id': 'CHEMBL710'}, 'observation_1': \"Properties of CHEMBL710:. molecular weight 372.6 Da. ALogP 3.81 (lipophilic). TPSA 58.2 Ų (good permeability expected). 2 H-bond donors and 2 H-bond acceptors. 1 rotatable bonds (rigid). compliant with Lipinski's Rule of Five. classified as Small molecule.\", 'thought_2': 'The compound properties confirm that CHEMBL710 is indeed Finasteride. The next step is to search for its bioactivities, specifically looking for any information related to cardiac fibroblasts or fibrosis. I will use `CHEMBL__get_compound_bioactivities_summary` for this. Since the target assay is about reversing an activated phenotype, I will look for activities that might indicate such a reversal, though direct evidence might be scarce.', 'tool_name_2': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_2': {'chembl_id': 'CHEMBL710'}, 'observation_2': 'Bioactivity summary for CHEMBL710:\\n\\n• Steroid 5-alpha-reductase 1 (CHEMBL1787): IC50 = 10.0 nM, Ki = 6.8 nM, Inhibition = 10.0 %\\n\\n• Steroid 5-alpha-reductase 2 (CHEMBL1856): IC50 < 0.1 nM, IC50 ratio = 0.6 None\\n\\n• Rattus norvegicus (CHEMBL376): Conversion = 39.0 %, Reduction in prostate weight = 100.0 %\\n\\n• Unchecked (CHEMBL612545): IC50 = 33.0 nM, Ki = 150.0 nM\\n\\n• 3-beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase type I (CHEMBL1958): Ki = 11000 nM\\n(Showing top 5 of 9 targets with activity data)', 'thought_3': 'The bioactivity summary shows that Finasteride primarily acts as an inhibitor of steroid 5-alpha-reductase enzymes. While this is its known mechanism of action, there is no direct information in this summary about its effects on cardiac fibroblasts or fibrosis. To better understand its potential efficacy in the context of cardiac fibroblast phenotype reversal, I should check if Finasteride is approved as a drug and what its indications are. This might provide indirect clues or highlight related research. I will use `CHEMBL__get_drug_info_summary` for this.', 'tool_name_3': 'CHEMBL__get_drug_info_summary', 'tool_args_3': {'chembl_id': 'CHEMBL710'}, 'observation_3': 'CHEMBL710 is an approved drug (first approved: 1992)\\n\\nMechanisms of action: Steroid 5-alpha-reductase 2 inhibitor (INHIBITOR) targeting CHEMBL1856\\n\\nDrug indications: non-small cell lung carcinoma (Phase 2.0) (Carcinoma, Non-Small-Cell Lung), prostate carcinoma (Phase 4.0) (Prostatic Neoplasms), benign prostatic hyperplasia (Phase 4.0) (Prostatic Hyperplasia), retinopathy (Phase 2.0) (Retinal Diseases), androgenetic alopecia (Phase 4.0) (Alopecia), prostate adenocarcinoma (Phase 4.0) (Prostatic Neoplasms), acne (Phase 2.0) (Acne Vulgaris), hypogonadism (Phase 1.0) (Hypogonadism), prostate cancer (Phase 2.0) (Prostatic Neoplasms, Castration-Resistant), hyperplasia (Phase 0.5) (Hyperplasia)', 'thought_4': \"The drug information confirms Finasteride is approved for conditions like benign prostatic hyperplasia and prostate cancer, which are related to androgenetic alopecia. However, there's no direct link to cardiac fibroblast activation or fibrosis in its indications or mechanism of action. The primary mechanism is steroid 5-alpha-reductase inhibition. Without direct evidence of Finasteride's effect on cardiac fibroblasts, I cannot confidently predict its efficacy. I will search PubChem for Finasteride to see if there's any bioassay data that might be relevant to cardiac fibrosis or fibroblast activation.\", 'tool_name_4': 'PUBCHEM__search_pubchem_cid', 'tool_args_4': {'query': 'Finasteride'}, 'observation_4': \"Found PubChem CID 57363 ((1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-tert-butyl-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide) for 'Finasteride'\"},\n",
       "      reasoning=\"Finasteride's known mechanism of action is the inhibition of steroid 5-alpha-reductase. Its approved indications are primarily related to androgen-dependent conditions such as benign prostatic hyperplasia and androgenetic alopecia. There is no direct evidence in the retrieved information (ChEMBL, drug indications) that suggests Finasteride has any effect on cardiac fibroblasts or the process of cardiac fibrosis. Therefore, its efficacy in reversing the activated cardiac fibroblast phenotype cannot be predicted based on the available data.\",\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.1\n",
       "  ),\n",
       "  0.7631090441879179),\n",
       " (Example({'compound_name': 'Veliparib', 'cf_efficacy': 0.718292313566172}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to estimate the efficacy of Veliparib in reversing the activated cardiac fibroblast phenotype. The provided assay details involve a custom in vitro experiment. To estimate efficacy, I need to find any existing preclinical data on Veliparib in a cardiac fibrosis context. I will start by searching for Veliparib on ChEMBL to get its ChEMBL ID, and then look for bioactivity data.', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Veliparib'}, 'observation_0': \"Found 2 compound(s) matching 'Veliparib': \\n - CHEMBL506871 (VELIPARIB)\\n - CHEMBL497608 (None)\", 'thought_1': \"I have found two ChEMBL IDs for Veliparib. CHEMBL506871 is explicitly named 'VELIPARIB', so I will proceed with this ID. My next step is to get the bioactivity summary for this compound to see if there's any relevant preclinical data for cardiac fibrosis.\", 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL506871'}, 'observation_1': 'Bioactivity summary for CHEMBL506871:\\n\\n• Mus musculus (CHEMBL375): Cmax = 6549 nM, F = 92.0 %, T1/2 = 1.6 hr, AUC = 2200 ng.hr.mL-1, CL = 68.3 mL.min-1.kg-1, Vdss = 9.4 L.kg-1\\n\\n• Rattus norvegicus (CHEMBL376): Cmax = 2047 nM, F = 61.0 %, T1/2 = 1.2 hr, AUC = 1500 ng.hr.mL-1, CL = 33.3 mL.min-1.kg-1, Vdss = 3.6 L.kg-1\\n\\n• Canis familiaris (CHEMBL373): Cmax = 3275 nM, F = 72.0 %, T1/2 = 2.7 hr, AUC = 3200 ng.hr.mL-1, CL = 10.0 mL.min-1.kg-1, Vdss = 2.2 L.kg-1\\n\\n• Cynomolgus monkey (CHEMBL613847): Cmax = 1228 nM, F = 56.0 %, T1/2 = 1.9 hr, AUC = 1300 ng.hr.mL-1, CL = 18.3 mL.min-1.kg-1, Vdss = 3.1 L.kg-1\\n\\n• Plasma (CHEMBL613424): PPB = 41.0 %\\n(Showing top 5 of 17 targets with activity data)', 'thought_2': 'The bioactivity summary for Veliparib (CHEMBL506871) does not contain information directly related to cardiac fibrosis or fibroblast activation. The provided data pertains to pharmacokinetic properties in different species. To assess efficacy in reversing the activated cardiac fibroblast phenotype, I need to look for data that is more specific to this context. I will try searching PubChem for Veliparib to see if there is any relevant bioassay data.', 'tool_name_2': 'PUBCHEM__search_pubchem_cid', 'tool_args_2': {'query': 'Veliparib'}, 'observation_2': \"Found PubChem CID 11960529 (2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide) for 'Veliparib'\", 'thought_3': 'I have found the PubChem CID for Veliparib (CID 11960529). Now I need to search for bioassay data related to this compound that might indicate its efficacy in reversing the activated cardiac fibroblast phenotype. I will use the `PUBCHEM__get_bioassay_summary` tool for this.', 'tool_name_3': 'PUBCHEM__get_bioassay_summary', 'tool_args_3': {'cid': '11960529'}, 'observation_3': 'Bioassay summary for CID 11960529:\\nTested in 1122 assays - 107 active, 261 inactive\\n\\nActive in:\\n• AID 348218: Cmax in Beagle dog at 2.5 mg/kg, po \\n\\n• AID 348224: Cmax in cynomolgus monkey at 2.5 mg/kg, po \\n\\n• AID 412651: Inhibition of human recombinant PARP1 \\n\\n• AID 412652: Inhibition of human recombinant PARP2 \\n\\n• AID 412653: Inhibition of PARP1 in human C41 cells \\n\\n(Showing 5 of 107 active assays)', 'thought_4': \"The bioassay summary for Veliparib shows it has been tested in many assays, with some indicating activity. However, none of the listed active assays are directly related to cardiac fibroblast activation or fibrosis reversal. The active assays are primarily related to pharmacokinetic properties (Cmax in dogs and monkeys) and PARP inhibition. Since there's no direct evidence of efficacy in the context of cardiac fibrosis, and no other tools seem immediately relevant to finding this specific type of efficacy data, I should conclude that I cannot estimate the efficacy based on the available tools and data.\", 'tool_name_4': 'finish', 'tool_args_4': {}, 'observation_4': 'Completed.'},\n",
       "      reasoning='The search for Veliparib on ChEMBL and PubChem did not yield any preclinical data directly related to its efficacy in reversing the activated cardiac fibroblast phenotype or in the context of cardiac fibrosis. The available bioactivity data pertains to pharmacokinetic properties and PARP inhibition, which are not directly relevant to the specified assay. Therefore, the efficacy cannot be predicted based on the available information.',\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.1\n",
       "  ),\n",
       "  0.718292313566172),\n",
       " (Example({'compound_name': 'GSK1904529A', 'cf_efficacy': 0.6779650234402858}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to estimate the efficacy of GSK1904529A in reversing the activated cardiac fibroblast phenotype. The described assay is a custom in vitro assay. To assess efficacy, I need to find any existing preclinical data on this compound in a cardiac fibrosis context. I will start by searching for the compound in ChEMBL to get its ChEMBL ID and then look for its bioactivities.', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'GSK1904529A'}, 'observation_0': \"Found 1 compound(s) matching 'GSK1904529A': \\n - CHEMBL466397 (None)\", 'thought_1': \"I have found the ChEMBL ID for GSK1904529A, which is CHEMBL466397. The next step is to retrieve its bioactivities to see if there's any relevant information regarding cardiac fibrosis or similar contexts. I will use the `CHEMBL__get_compound_bioactivities_summary` tool for this.\", 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL466397'}, 'observation_1': 'Bioactivity summary for CHEMBL466397:\\n\\n• Unchecked (CHEMBL612545): Potency None 331.7 nM\\n\\n• Insulin receptor (CHEMBL1981): IC50 = 19.0 nM, Ki = 1.3 nM\\n\\n• Insulin-like growth factor I receptor (CHEMBL1957): IC50 = 22.0 nM, Ki = 1.6 nM\\n\\n• NON-PROTEIN TARGET (CHEMBL3879801): IC50 = 35.0 nM\\n\\n• Rattus norvegicus (CHEMBL376): AUC = 1220 ng.hr.mL-1, CL = 5.8 mL.min-1.kg-1, Vdss = 7.5 L.kg-1, F = 63.0 %\\n(Showing top 5 of 20 targets with activity data)', 'thought_2': \"The bioactivity summary for GSK1904529A (CHEMBL466397) shows activity against insulin receptor and insulin-like growth factor I receptor, with IC50 values in the nanomolar range. However, there is no direct information about its efficacy in reversing the activated cardiac fibroblast phenotype or in the context of cardiac fibrosis. To get a better understanding of the compound's properties and potential therapeutic uses, I will search for drug information. I will use the `CHEMBL__get_drug_info_summary` tool for this. If this does not yield relevant information, I will consider searching PubChem.\", 'tool_name_2': 'CHEMBL__get_drug_info_summary', 'tool_args_2': {'chembl_id': 'CHEMBL466397'}, 'observation_2': 'CHEMBL466397 is not an approved drug', 'thought_3': \"The compound GSK1904529A (CHEMBL466397) is not an approved drug. The previous bioactivity data focused on insulin receptor and IGF-1 receptor, which are not directly related to cardiac fibroblasts or fibrosis. Since there's no direct evidence of efficacy in the desired context from ChEMBL, I will now search PubChem for this compound to see if there's any relevant bioassay data or drug information that might shed light on its potential effects on cardiac fibroblasts. I will start by searching for the compound's CID using `PUBCHEM__search_pubchem_cid`.\", 'tool_name_3': 'PUBCHEM__search_pubchem_cid', 'tool_args_3': {'query': 'GSK1904529A'}, 'observation_3': \"Found PubChem CID 25124816 (N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonylpiperazin-1-yl)piperidin-1-yl]anilino]pyrimidin-4-yl]imidazo[1,2-a]pyridin-2-yl]-2-methoxybenzamide) for 'GSK1904529A'\", 'thought_4': \"I have found the PubChem CID for GSK1904529A, which is 25124816. Now I will use this CID to retrieve bioassay summary information from PubChem using the `PUBCHEM__get_bioassay_summary` tool. This might provide more specific data related to the compound's biological activities, potentially including information relevant to cardiac fibroblast phenotype.\", 'tool_name_4': 'PUBCHEM__get_bioassay_summary', 'tool_args_4': {'cid': '25124816'}, 'observation_4': 'Bioassay summary for CID 25124816:\\nTested in 562 assays - 138 active, 173 inactive\\n\\nActive in:\\n• AID 371373: Inhibition of GST-tagged IGF1R (957-1367) expressed in baculovirus by time-resolved fluorescence ... \\n\\n• AID 371374: Inhibition of human IGF1R autophosphorylation in transfected mouse NIH3T3 cells \\n\\n• AID 371613: Inhibition of GST-tagged insulin receptor expressed in baculovirus by time-resolved fluorescence ... \\n\\n• AID 371618: Inhibition of Aurora B \\n\\n• AID 371622: Inhibition of human insulin receptor autophosphorylation in transfected mouse NIH3T3 cells \\n\\n(Showing 5 of 138 active assays)'},\n",
       "      reasoning=\"The compound GSK1904529A has been identified with ChEMBL ID CHEMBL466397 and PubChem CID 25124816. Bioactivity data from both ChEMBL and PubChem indicate that GSK1904529A is a potent inhibitor of the insulin receptor and the insulin-like growth factor I receptor (IGF-1R). While these targets are involved in cellular growth and metabolism, there is no direct evidence in the retrieved data linking GSK1904529A to the modulation of cardiac fibroblast activation or fibrosis. The assay described in the prompt specifically measures the reversal of the activated cardiac fibroblast phenotype. Given the lack of direct evidence for this specific effect, and the compound's known mechanism of action being unrelated to established pathways for reversing cardiac fibrosis, the predicted efficacy is low. The confidence in this prediction is moderate, as while there's no positive evidence, the absence of negative evidence also means it's not definitively ineffective, but its known targets don't align with the desired outcome.\",\n",
       "      predicted_efficacy=0.1,\n",
       "      confidence=0.4\n",
       "  ),\n",
       "  0.5779650234402858),\n",
       " (Example({'compound_name': 'KU-55933', 'cf_efficacy': 0.6758212843500732}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to estimate the efficacy of KU-55933 in reversing the activated cardiac fibroblast phenotype. The assay involves applying the compound to fibroblasts and measuring the morphological changes using Cell Painting and a machine learning classifier. The efficacy is defined as the mean predicted probability of a cell being non-failing.\\n\\nTo start, I need to find information about KU-55933. I will begin by searching for its ChEMBL ID. This will allow me to retrieve more detailed information from ChEMBL.', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'KU-55933'}, 'observation_0': \"Found 5 compound(s) matching 'KU-55933': \\n - CHEMBL222102 (KU-55933)\\n - CHEMBL380648 (None)\\n - CHEMBL1078983 (Ku-0063794)\\n - CHEMBL2140173 (None)\\n - CHEMBL196444 (None)\", 'thought_1': 'I have found the ChEMBL ID for KU-55933, which is CHEMBL222102. The next step is to get more information about this compound, specifically its bioactivities, to assess its potential efficacy. I will use the `get_compound_bioactivities_summary` tool.', 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL222102'}, 'observation_1': 'Bioactivity summary for CHEMBL222102:\\n\\n• Serine-protein kinase ATM (CHEMBL3797): IC50 = 13.0 nM, Ki = 2.2 nM\\n\\n• DNA-dependent protein kinase (CHEMBL3142): IC50 = 1800 nM\\n\\n• Serine/threonine-protein kinase MARK1 (CHEMBL5940): Residual Activity = 96.0 %\\n\\n• Serine/threonine-protein kinase SRPK3 (CHEMBL5415): Residual Activity = 94.0 %\\n\\n• Serine/threonine-protein kinase NEK7 (CHEMBL4849): Residual Activity = 109.0 %\\n(Showing top 5 of 32 targets with activity data)', 'thought_2': \"The bioactivity summary shows that KU-55933 is a potent inhibitor of ATM (IC50 = 13.0 nM, Ki = 2.2 nM). ATM is a kinase involved in DNA damage response. While this is a significant finding, it doesn't directly tell us about its efficacy in reversing the activated cardiac fibroblast phenotype. The provided assay description focuses on morphological changes.\\n\\nTo assess efficacy, I need to find studies that specifically tested KU-55933 in a cardiac fibroblast context or a similar cellular model related to fibrosis. Since the previous search focused on ChEMBL, I will now try searching PubChem for bioassay data related to KU-55933. This might reveal relevant in vitro assays.\", 'tool_name_2': 'PUBCHEM__search_pubchem_cid', 'tool_args_2': {'query': 'KU-55933'}, 'observation_2': \"Found PubChem CID 5278396 (2-morpholin-4-yl-6-thianthren-1-ylpyran-4-one) for 'KU-55933'\", 'thought_3': 'I have found the PubChem CID for KU-55933, which is 5278396. Now I need to get the bioassay summary for this compound from PubChem to see if there are any relevant assays that could indicate its efficacy in reversing the activated cardiac fibroblast phenotype.', 'tool_name_3': 'PUBCHEM__get_bioassay_summary', 'tool_args_3': {'cid': '5278396'}, 'observation_3': 'Bioassay summary for CID 5278396:\\nTested in 1410 assays - 74 active, 198 inactive\\n\\nActive in:\\n• AID 129: NCI human tumor cell line growth inhibition assay. Data for the A498 Renal cell line \\n\\n• AID 281337: Inhibition of DNA-PK in HeLa cell nuclear extracts \\n\\n• AID 281339: Inhibition of ATM kinase \\n\\n• AID 503482: Suppression of senescence in human BJ cells assessed as increase in cell number at 10 uM after 10... \\n\\n• AID 503486: Inhibition of ataxia telangiectasia-mutated in human BJ cells assessed as increase in cell number... \\n\\n(Showing 5 of 74 active assays)', 'thought_4': \"The PubChem bioassay summary indicates that KU-55933 inhibits ATM kinase and DNA-PK, and also shows suppression of senescence in human BJ cells. While senescence and cardiac fibroblast activation might share some pathways, there's no direct evidence of efficacy in reversing the activated cardiac fibroblast phenotype. The provided assay description is very specific about the Cell Painting readout and ML classifier. Since I haven't found direct evidence of efficacy for this specific application, and the available data doesn't directly translate to the requested efficacy metric, I will conclude that I cannot predict the efficacy with high confidence based on the current information. Therefore, I will finish the task.\", 'tool_name_4': 'finish', 'tool_args_4': {}, 'observation_4': 'Completed.'},\n",
       "      reasoning=\"KU-55933 is a known inhibitor of ATM kinase (IC50 = 13.0 nM, Ki = 2.2 nM from ChEMBL) and DNA-PK. PubChem data also shows its activity in suppressing senescence in human BJ cells. While ATM inhibition and senescence suppression can be related to cellular stress and activation pathways, there is no direct evidence in the literature or databases searched that specifically demonstrates KU-55933's efficacy in reversing the activated cardiac fibroblast phenotype using the described Cell Painting + ML readout. Without specific experimental data on this compound in this particular assay or a very similar context, predicting a precise efficacy value is not possible. Therefore, the predicted efficacy is set to 0, reflecting a lack of evidence for efficacy in this specific context, and the confidence is low.\",\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.1\n",
       "  ),\n",
       "  0.6758212843500732),\n",
       " (Example({'compound_name': 'PHA-665752', 'cf_efficacy': 0.6482624882747973}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': \"The user wants to assess the efficacy of PHA-665752 in reversing the activated cardiac fibroblast phenotype. The primary goal is to find preclinical data on this compound in a cardiac fibrosis context. I should start by searching for the compound in both ChEMBL and PubChem to gather information. I'll begin with ChEMBL to get its ChEMBL ID, which can then be used to retrieve more detailed information.\", 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'PHA-665752'}, 'observation_0': \"Found 5 compound(s) matching 'PHA-665752': \\n - CHEMBL450786 (PHA-665752)\\n - CHEMBL1230607 (PHA-793887)\\n - CHEMBL2086586 (None)\\n - CHEMBL214268 (PHA-543613)\\n - CHEMBL225519 (None)\", 'thought_1': 'The search for \"PHA-665752\" in ChEMBL returned multiple results, with CHEMBL450786 being the most relevant match for the query compound. The next step is to get more information about this compound using its ChEMBL ID. I should use the `CHEMBL__get_compound_bioactivities_summary` tool to check for any relevant bioactivity data, especially in the context of cardiac fibrosis or related targets.', 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL450786'}, 'observation_1': 'Bioactivity summary for CHEMBL450786:\\n\\n• NON-PROTEIN TARGET (CHEMBL3879801): Activity = 0.2 None\\n\\n• Unchecked (CHEMBL612545): IC50 > 10000 nM\\n\\n• Hepatocyte growth factor receptor (CHEMBL3717): EC50 = 42.0 nM, IC50 = 9.0 nM\\n\\n• Macrophage-stimulating protein receptor (CHEMBL2689): EC50 = 900.0 nM, IC50 = 68.0 nM\\n\\n• Vascular endothelial growth factor receptor 2 (CHEMBL279): EC50 = 2500 nM, IC50 = 200.0 nM\\n(Showing top 5 of 27 targets with activity data)', 'thought_2': \"The bioactivity summary for PHA-665752 (CHEMBL450786) shows activity against targets like Hepatocyte growth factor receptor (MET), Macrophage-stimulating protein receptor, and Vascular endothelial growth factor receptor 2. While these are related to cell growth and angiogenesis, they are not directly related to cardiac fibrosis. The prompt specifically asks for preclinical data in a cardiac fibrosis context. Therefore, I need to search PubChem for more information on this compound, specifically looking for bioassays or drug summaries that might relate to cardiac fibroblasts or fibrosis. I will start by searching PubChem for the compound's CID.\", 'tool_name_2': 'PUBCHEM__search_pubchem_cid', 'tool_args_2': {'query': 'PHA-665752'}, 'observation_2': \"Found PubChem CID 10461815 ((3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-[[3,5-dimethyl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-1H-pyrrol-2-yl]methylidene]-1H-indol-2-one) for 'PHA-665752'\", 'thought_3': \"I have found the PubChem CID for PHA-665752, which is 10461815. Now I need to retrieve information about this compound from PubChem. The prompt emphasizes finding preclinical data in a cardiac fibrosis context. I will use `PUBCHEM__get_bioassay_summary` to look for any relevant bioassays. If that doesn't yield direct results, I can explore other PubChem tools like `PUBCHEM__get_drug_summary` or `PUBCHEM__get_cid_properties` for more general information.\", 'tool_name_3': 'PUBCHEM__get_bioassay_summary', 'tool_args_3': {'cid': '10461815'}, 'observation_3': 'Bioassay summary for CID 10461815:\\nTested in 1524 assays - 260 active, 87 inactive\\n\\nActive in:\\n• AID 73: NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line \\n\\n• AID 2302: Inhibition of P. falciparum Dd2 \\n\\n• AID 2306: Inhibition of P. falciparum 3D7 \\n\\n• AID 383062: Inhibition of EGFR \\n\\n• AID 383065: Inhibition of c-Met \\n\\n(Showing 5 of 260 active assays)', 'thought_4': \"The bioassay summary from PubChem indicates that PHA-665752 has been tested in various assays, including one for c-Met inhibition, which aligns with the ChEMBL result of activity against Hepatocyte growth factor receptor. However, none of the listed assays directly relate to cardiac fibroblasts or fibrosis. The prompt emphasizes finding preclinical data in a cardiac fibrosis context. Since direct evidence is lacking in the bioassay results, I should try to find more general drug information or properties that might indirectly suggest efficacy in this context. I will use `PUBCHEM__get_drug_summary` to see if there's any information about its therapeutic uses or pharmacology that could be relevant.\", 'tool_name_4': 'PUBCHEM__get_drug_summary', 'tool_args_4': {'cid': '10461815'}, 'observation_4': 'No drug information available for CID 10461815'},\n",
       "      reasoning='The compound PHA-665752 is a known inhibitor of the c-Met receptor tyrosine kinase. While c-Met signaling can play a role in cell proliferation and migration, there is no direct preclinical evidence in the literature or in the databases searched (ChEMBL, PubChem) to suggest that PHA-665752 has been tested or shown to be effective in reversing activated cardiac fibroblast phenotype or treating cardiac fibrosis. The bioassays and bioactivity data found are related to cancer cell lines, parasitic infections, and other receptor tyrosine kinases, but not specifically to cardiac fibroblasts or fibrosis. Therefore, based on the available information, the predicted efficacy is low, and the confidence in this prediction is also low due to the lack of relevant data.',\n",
       "      predicted_efficacy=0.1,\n",
       "      confidence=0.2\n",
       "  ),\n",
       "  0.5482624882747973),\n",
       " (Example({'compound_name': 'Nilotinib', 'cf_efficacy': 0.6380639938634679}) (input_keys={'compound_name'}),\n",
       "  Prediction(\n",
       "      trajectory={'thought_0': 'The user wants to estimate the efficacy of Nilotinib in reversing the activated cardiac fibroblast phenotype. The provided assay details are specific and involve a custom in vitro readout. Since this is a specific assay, it\\'s unlikely that direct results for this exact assay will be found in public databases. However, I should first search for existing preclinical data on Nilotinib in a cardiac fibrosis context. I will start by searching for Nilotinib in ChEMBL to get its ChEMBL ID, and then look for its bioactivities. I will also search PubChem for similar information.\\n\\nFirst, I will search ChEMBL for the compound name \"Nilotinib\".', 'tool_name_0': 'CHEMBL__search_chembl_id', 'tool_args_0': {'query': 'Nilotinib'}, 'observation_0': \"Found 3 compound(s) matching 'Nilotinib': \\n - CHEMBL255863 (NILOTINIB)\\n - CHEMBL1201740 (NILOTINIB HYDROCHLORIDE MONOHYDRATE)\\n - CHEMBL5085550 (None)\", 'thought_1': \"I have found three ChEMBL IDs for Nilotinib. CHEMBL255863 seems to be the primary ID for Nilotinib. I will now retrieve the bioactivity summary for this compound to see if there's any relevant information regarding cardiac fibrosis or fibroblast activation.\", 'tool_name_1': 'CHEMBL__get_compound_bioactivities_summary', 'tool_args_1': {'chembl_id': 'CHEMBL255863'}, 'observation_1': 'Bioactivity summary for CHEMBL255863:\\n\\n• NON-PROTEIN TARGET (CHEMBL3879801): IC50 = 3.4 nM\\n\\n• Bcr/Abl fusion protein (CHEMBL2096618): IC50 = 20.0 nM\\n\\n• K562 (CHEMBL385): IC50 = 6.5 nM\\n\\n• Stem cell growth factor receptor (CHEMBL1936): IC50 = 158.0 nM\\n\\n• Serine/threonine-protein kinase RAF (CHEMBL1906): IC50 = 1100 nM\\n(Showing top 5 of 38 targets with activity data)', 'thought_2': 'The bioactivity summary shows that Nilotinib is a potent inhibitor of Bcr/Abl fusion protein and K562 cells, which is consistent with its known use as a cancer therapeutic. However, there is no direct information about its efficacy in reversing the activated cardiac fibroblast phenotype or in the context of cardiac fibrosis. I should now search PubChem for Nilotinib to see if there is any relevant information there, particularly regarding bioassays or drug summaries that might touch upon cardiac effects.', 'tool_name_2': 'PUBCHEM__search_pubchem_cid', 'tool_args_2': {}, 'observation_2': 'Execution error in PUBCHEM__search_pubchem_cid: \\nTraceback (most recent call last):\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/predict/react.py\", line 111, in forward\\n    trajectory[f\"observation_{idx}\"] = self.tools[pred.next_tool_name](**pred.next_tool_args)\\n                                       ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/utils/callback.py\", line 326, in sync_wrapper\\n    return fn(instance, *args, **kwargs)\\n           ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\\n  File \"/Users/roshankern/Desktop/Github/cf-compound-selection-demo/backend/.venv/lib/python3.12/site-packages/dspy/adapters/types/tool.py\", line 176, in __call__\\n    result = self.func(**parsed_kwargs)\\n             ^^^^^^^^^^^^^^^^^^^^^^^^^^\\nTypeError: search_pubchem_cid() missing 1 required positional argument: \\'query\\'', 'thought_3': \"The previous tool call to PUBCHEM__search_pubchem_cid failed because the 'query' argument was missing. I need to provide the compound name 'Nilotinib' as the query to search PubChem for its CID. After obtaining the CID, I will proceed to get its bioassay summary to look for any relevant information regarding cardiac fibrosis or fibroblast activation.\", 'tool_name_3': 'PUBCHEM__search_pubchem_cid', 'tool_args_3': {'query': 'Nilotinib'}, 'observation_3': \"Found PubChem CID 644241 (4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide) for 'Nilotinib'\", 'thought_4': 'I have found the PubChem CID for Nilotinib (644241). Now I will retrieve the bioassay summary for this CID to check for any relevant information regarding cardiac fibrosis or fibroblast activation. If no relevant information is found, I will then proceed to check the drug summary.', 'tool_name_4': 'PUBCHEM__get_bioassay_summary', 'tool_args_4': {'cid': '644241'}, 'observation_4': 'Bioassay summary for CID 644241:\\nTested in 2457 assays - 573 active, 709 inactive\\n\\nActive in:\\n• AID 121: NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line \\n\\n• AID 125: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line \\n\\n• AID 322453: Inhibition of Raf1 kinase \\n\\n• AID 421473: Antitumor activity against mouse BA/F3 cells expressing wild type Bcr-Abl xenografted in CB17 SCI... \\n\\n• AID 421475: Antitumor activity against mouse BA/F3 cells expressing wild type Bcr-Abl xenografted in CB17 SCI... \\n\\n(Showing 5 of 573 active assays)'},\n",
       "      reasoning='The search for Nilotinib in ChEMBL and PubChem did not yield any direct preclinical data related to its efficacy in reversing activated cardiac fibroblast phenotype or in the context of cardiac fibrosis. The available bioactivity data primarily focuses on its known mechanism of action as a tyrosine kinase inhibitor, particularly against Bcr/Abl, and its anti-cancer effects. Without specific evidence linking Nilotinib to cardiac fibroblast modulation or fibrosis reversal in preclinical studies, it is not possible to predict its efficacy for this specific assay. Therefore, the predicted efficacy is set to 0, and the confidence is low due to the lack of relevant evidence.',\n",
       "      predicted_efficacy=0.0,\n",
       "      confidence=0.1\n",
       "  ),\n",
       "  0.6380639938634679)]"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evaluation.results"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (cf-compound-selection-backend)",
   "language": "python",
   "name": "cf-compound-selection-backend"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.4"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
